A dip in ransomware volumes points to a more targeted approach focused on vulnerability exploitation

Japanese Pharma Companies Turning to CDMOs Earlier in Product Life Cycle
Japanese pharmaceutical companies are engaging CDMOs earlier in the development cycle, as increasing complexity in peptide programs places greater strain on in-house capabilities, according to


